Glaukos (GKOS) Earnings Date & Reports

Key Takeaways

• Analysts expect Q1 2026 revenue of $137 million, representing 28% year-over-year growth from $107 million in Q1 2025.
• Consensus EPS forecast calls for a loss of $0.28 per share, narrower than prior quarters amid ongoing investments.
• U.S. Glaucoma segment, fueled by iDose TR, remains key focus after 53% growth to $86 million in Q4 2025.
• Company reaffirmed 2026 full-year revenue guidance of $600-620 million, implying sustained momentum.
• Recent permanent J-code for Epioxa could boost Cornea segment reimbursement and adoption.
• Glaukos holds $283 million in cash with no debt, supporting R&D and commercialization efforts.

Earnings Context and Why It Matters

Glaukos Corporation, a leader in innovative therapies for glaucoma and corneal diseases, enters Q1 2026 earnings with strong tailwinds from product launches. The company's micro-invasive glaucoma surgery (MIGS) portfolio, including the iDose TR sustained-release implant, drove U.S. Glaucoma sales up 53% in Q4 2025 to $86.4 million. Full-year 2025 revenue hit a record $507 million, up 32% year-over-year, underscoring execution amid a competitive eye care market. Investors watch this report closely as it tests sustained growth against rising SG&A (selling, general, and administrative) expenses and the Epioxa transition from Photrexa, which incurred a $113 million impairment last quarter. A solid Q1 could affirm Glaukos' path to profitability while highlighting demand for its dropless platforms.

Earnings Expectations

Wall Street anticipates Q1 2026 revenue of $137.03 million on average from 11 analysts, a 28% increase from $106.7 million in Q1 2025, driven by Glaucoma momentum. EPS consensus points to a $0.28 loss per share (13 analysts), reflecting heavy investments in commercialization and R&D (research and development).

Glaukos has a track record of revenue beats, including Q1 2025's $106.7 million topping estimates and Q4 2025's $143.1 million exceeding forecasts by 5%. Key metrics to monitor include U.S. Glaucoma growth, iDose TR units implanted, non-GAAP gross margins (85% in Q4), and updates on 2026 guidance ($600-620 million). The stock has shown volatility post-earnings, rising 13% after Q4 despite an EPS miss due to revenue strength and outlook.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to uncover potential plays in the healthcare sector like GKOS.

Market Reaction and Investor Sentiment

Ahead of April 29 results, Glaukos shares trade around $121, up modestly YTD amid optimism for iDose TR ramp-up but tempered by expense growth concerns. Sentiment leans positive on revenue trajectory, with analysts maintaining Buy ratings and $138 average price target. Risks include margin pressure from SG&A (up 37% in Q4) and Epioxa transition execution. Historical reactions vary: Q4 shares jumped 13% on beats, while prior misses weighed on sentiment.

Forward Outlook and Key Factors to Monitor

Following Q1, reaffirmation of $600-620 million 2026 revenue guidance will be pivotal, implying 21% growth at midpoint versus FY2025. Investors should track iDose TR adoption, as early U.S. launch data showed strong uptake fueling Glaucoma's 42% Q4 growth.

Epioxa, with its new permanent J-code (HCPCS reimbursement code) effective recently, could accelerate Cornea segment recovery post-impairment. Non-GAAP gross margins near 85% signal supply chain efficiency, but SG&A and R&D trends merit scrutiny amid $94 million quarterly spend.

Broader catalysts include international Glaucoma expansion and pipeline progress in dropless technologies. Cash position supports investments without dilution risks. Balanced execution here positions Glaukos for multi-year growth in $10 billion addressable glaucoma market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations